Otros idiomas Syros Pharmaceuticals, Inc.

Acciones

SYRS

US87184Q2066

Mercado cerrado - Nasdaq Otros sitios de cotización 22:00:00 02/05/2024			Varia. Cinco días.	Varia. 1 de enero.
5,2 ^USD	-4,41 %		+2,56 %	-33,25 %

09/04	Actualización del sector: Los valores del sector sanitario cotizan mixtos a última hora de la tarde	MT
09/04	Syros obtiene la etiqueta de vía rápida para el tamibaroteno en el tratamiento de la leucemia mieloide aguda; las acciones suben	MT

Otros idiomas

Desbloquee todas las noticias sobre todas las empresas: ¡No vuelvas a perderse una oportunidad de inversión rentable!

Inscripción 100% Gratuita

Sector Update: Health Care Stocks Mixed in Late Afternoon Trading	09/04
Syros Gets Fast Track Label For Tamibarotene to Treat Acute Myeloid Leukemia; Shares Rise	09/04
Syros Gets FDA Fast-Track Designation for Tamibarotene	09/04
Syros Receives Fast Track Designation from the FDA for Tamibarotene for the Treatment of Newly Diagnosed Unfit AML with RARA gene overexpression	09/04
Syros Pharmaceuticals, Inc. Receives Fast Track Designation from the FDA for Tamibarotene for the Treatment of Newly Diagnosed Unfit AML with RARA gene overexpression	09/04
Syros Reports Inducement Grants under Nasdaq Listing Rule 5635(4)	03/04
Syros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	02/04
Health Care Rises as Upward Momentum Builds -- Health Care Roundup	28/03
Health Care Jumps as Upward Momentum Builds -- Health Care Roundup	27/03
Earnings Flash (SYRS) SYROS PHARMACEUTICALS Reports Q4 Revenue $387,000	27/03
Syros Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Corporate Update	27/03
Syros Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	27/03
Syros Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	27/03
North American Morning Briefing : Stocks Edge -2-	27/03
Syros Pharmaceuticals Completes Enrollment of 190 People in Phase 3 Trial of Tamibarotene	25/03
Syros Announces Completion of Enrollment of 190 Patients Necessary to Support Primary Endpoint Analysis in SELECT-MDS-1 Phase 3 Trial	25/03
Syros Pharmaceuticals Announces Completion of Enrollment of 190 Patients Necessary to Support Primary Endpoint Analysis in Select-MDS-1 Phase 3 Trial	25/03
Syros to Report Fourth Quarter and Full Year 2023 Financial Results on Wednesday, March 27, 2024	20/03
Syros to Participate in TD Cowen 44th Annual Health Care Conference	27/02
Thinking about buying stock in Applied UV, Crowdstrike, Syros Pharmaceuticals, Captivision, or Polestar Automotive?	01/02

No hay resultados para esta búsqueda

Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Otros idiomas Syros Pharmaceuticals, Inc.

Acciones

SYRS

US87184Q2066

Otros idiomas

Filtros